Hadj Taieb M, Slimane H, Mhiri M, Ben Dhia R, Daoussi N, Frih-Ayed M
Acta Neurol Belg. 2024; 124(2):431-445.
PMID: 38396190
DOI: 10.1007/s13760-024-02477-1.
Giani T, Luppino A, Ferrara G
Paediatr Drugs. 2023; 25(2):165-191.
PMID: 36626047
PMC: 9838500.
DOI: 10.1007/s40272-022-00548-5.
Karabulut Y
Eur J Rheumatol. 2021; 8(4):223-227.
PMID: 34554909
PMC: 10176236.
DOI: 10.5152/eurjrheum.2021.20160.
Alibaz-Oner F, Direskeneli H
Curr Rheumatol Rep. 2021; 23(6):47.
PMID: 34014377
PMC: 8136102.
DOI: 10.1007/s11926-021-01011-z.
Alibaz-Oner F, Direskeneli H
Eur J Rheumatol. 2021; 8(4):217-222.
PMID: 33687828
PMC: 10176232.
DOI: 10.5152/eurjrheum.2020.20138.
Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet's syndrome: case series and literature review.
Liu J, Yan D, Wang Z, Yang Y, Zhang S, Wu D
Ther Adv Musculoskelet Dis. 2020; 12:1759720X20971908.
PMID: 33240406
PMC: 7675870.
DOI: 10.1177/1759720X20971908.
Understanding Behçet's Disease in the Context of Innate Immunity Activation.
Perazzio S, Andrade L, de Souza A
Front Immunol. 2020; 11:586558.
PMID: 33193413
PMC: 7606308.
DOI: 10.3389/fimmu.2020.586558.
Inflammatory Manifestations of Systemic Diseases in the Central Nervous System.
Lapides D, McDonald M
Curr Treat Options Neurol. 2020; 22(9):26.
PMID: 32834714
PMC: 7387810.
DOI: 10.1007/s11940-020-00636-2.
Treating the Different Phenotypes of Behçet's Syndrome.
Bettiol A, Hatemi G, Vannozzi L, Barilaro A, Prisco D, Emmi G
Front Immunol. 2020; 10:2830.
PMID: 31921115
PMC: 6915087.
DOI: 10.3389/fimmu.2019.02830.
Update on the treatment of Behçet's syndrome.
Esatoglu S, Hatemi G
Intern Emerg Med. 2019; 14(5):661-675.
PMID: 30684097
DOI: 10.1007/s11739-019-02035-1.
Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future.
Adeeb F, Stack A, Fraser A
Int J Rheumatol. 2017; 2017:2160610.
PMID: 29081805
PMC: 5610876.
DOI: 10.1155/2017/2160610.
Unmet Needs in the Pathogenesis and Treatment of Vasculitides.
Muratore F, Pazzola G, Soriano A, Pipitone N, Croci S, Bonacini M
Clin Rev Allergy Immunol. 2017; 54(2):244-260.
PMID: 28895041
DOI: 10.1007/s12016-017-8643-2.
Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.
Sota J, Rigante D, Lopalco G, Frediani B, Franceschini R, Galeazzi M
Rheumatol Int. 2017; 38(1):25-35.
PMID: 28752230
DOI: 10.1007/s00296-017-3775-5.
IL-6 blockade in the management of non-infectious uveitis.
Lopalco G, Fabiani C, Sota J, Lucherini O, Tosi G, Frediani B
Clin Rheumatol. 2017; 36(7):1459-1469.
PMID: 28528519
DOI: 10.1007/s10067-017-3672-z.
Tocilizumab reverses cerebral vasculopathy in a patient with homozygous SAMHD1 mutation.
Henrickson M, Wang H
Clin Rheumatol. 2017; 36(6):1445-1451.
PMID: 28289923
PMC: 5486483.
DOI: 10.1007/s10067-017-3600-2.
Behçet's Disease and Nervous System Involvement.
Kurtuncu M, Tuzun E, Akman-Demir G
Curr Treat Options Neurol. 2016; 18(5):19.
PMID: 27007988
DOI: 10.1007/s11940-016-0405-6.
Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.
Kampylafka E, Alexopoulos H, Dalakas M, Tzioufas A
Neurotherapeutics. 2015; 13(1):163-78.
PMID: 26510559
PMC: 4720664.
DOI: 10.1007/s13311-015-0393-3.
Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome.
Nava F, Ghilotti F, Maggi L, Hatemi G, Del Bianco A, Merlo C
Cochrane Database Syst Rev. 2014; (12):CD010729.
PMID: 25521793
PMC: 10594584.
DOI: 10.1002/14651858.CD010729.pub2.
Biological treatments in Behçet's disease: beyond anti-TNF therapy.
Caso F, Costa L, Rigante D, Lucherini O, Caso P, Bascherini V
Mediators Inflamm. 2014; 2014:107421.
PMID: 25061259
PMC: 4100257.
DOI: 10.1155/2014/107421.
Update on the therapy of Behçet disease.
Saleh Z, Arayssi T
Ther Adv Chronic Dis. 2014; 5(3):112-34.
PMID: 24790727
PMC: 3992825.
DOI: 10.1177/2040622314523062.
